RE:I can only hope…..and if your investment thesis is based on "hope"... what can I say....
Many have thought, "it'll be different this time", but it never is.. Management is actually very skilled at keeping just enough interest to get from one year to the next. Diluting existing shareholders a bit at a time...
They're always in discussions with partners, the next 6-9 months are always about to have transformative data and inflection points, and KOLs are always very excited...
But somehow, none of this ever translates into a deal/partnership... As much as you might
hope this succeeds, really, what are the chance based on past performance...?
- Trials that end without notice.
- leadership figures who disappear overnight without even so much as a thankyou from the company.
- Phase III trials ready to go and approved by FDA that don't materialise.
- Their only partner (Adlai Nortye) who no longer seems to have any interest in Pelareorep.
- Trials that run years longer than announced, and too little patient data to make statisical analyses on.
Is this all coincidence, just poor luck...? or is there something fundamentally wrong here... something that the market is actually pricing in... and why is a company on the cusp of great success being valued less than 90 million bucks.
On a positive note, PPS is so low now, how much more downside can there be ? less than a buck?